Navigation Links
Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
Date:5/28/2009

repair. GAM technology can also be applied to a number of other approaches benefiting from sustained localized release of therapeutic proteins and other agents. For more information about Cardium's Tissue Repair Company subsidiary, please visit www.t-r-co.com.

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic designed for use by interventional cardiologists as a potential one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com or view its most recent annual report on Form 10-K and other reports as filed with the Securities and Exchange Commission and available on the company's website.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MATRIX study or other human clinical trials can be conducted and completed in an efficient and successful manner, that product formulation enhancements will be successful or will effectively simplify or expand the use of product candidates or technologies, that the GAM technology can be successfully broadened or applied to additional wound healing or tissue repair opportunities, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedu
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Cardium Completes $6.0 Million Financing
6. Cardium Announces Investor Presentation and Corporate Update Webcast
7. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
8. Cardium Reports on Exchange Listing With NYSE Alternext US
9. Cardiums InnerCool Announces Launch of New Enhanced Website
10. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
11. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines ... analysis and forecast of revenue. The artificial lift market in ... in 2013 to around $7 billion by 2018, at a ... through the TOC of North America artificial lift market report, ... provides a glimpse of the segmentation in North America Artificial ...
(Date:7/25/2014)... Providence, RI (PRWEB) July 25, 2014 ... Island Quality Improvement Organization (QIO) was recently awarded ... from the Centers for Medicare & Medicaid Services ... to fourteen organizations across the United States, represent ... In order to successfully execute the contract initiatives, ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading healthcare ... Corporation, is introducing its newest solution in an upcoming ... Quality. , The webinar will be held twice on ... at 2 PM ET. For more information or to ... or call 866.799.2655. , In an environment of escalating ...
(Date:7/25/2014)... July 25, 2014 -- The Elizabeth Glaser Pediatric ... between the Medicines Patent Pool (MPP) and Gilead ... fumarate (TAF), a promising new HIV medication. The ... Conference (AIDS 2014) in Melbourne, Australia. , ... trials, early data suggests it could be a ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 2Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 3Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 4Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3
... updated the NCCN Guidelines for Venous Thromboembolic Disease, which ... (PE), and is a common condition in people with ... graduated compression stockings in prophylaxis and treatment, and a ... May 20 The National Comprehensive Cancer Network (NCCN) ...
... Alliance designed to benefit Californians with medical ... Medical Association (CMA), representing 35,000 physicians in ... the MedicAlert Foundation, the leading nonprofit providing ... teamed up to provide patients living with ...
... counseling also proved cost-effective, study finds , , WEDNESDAY, ... program that promoted exercise, healthy eating and quitting ... to moderate chronic obstructive pulmonary disease (COPD) and ... patients in the study were randomly assigned to ...
... Market is Reflected in Burgeoning Pipeline of More than ... from Decision ResourcesWALTHAM, Mass., May 20 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the launch ... over the next 10 years will drive the type ...
... partnership with Axway to provide innovative solutions ... technologists to address the challenges of implementing ... cost-effective manner.BELLEVUE, Wash., May 20 Edifecs, ... simplification and systems interoperability, and Axway, a ...
... Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share, payable on June 30, 2009 to holders ... rate is $1.32 per share. About BD BD is ... sells medical devices, instrument systems and reagents. The Company is ...
Cached Medicine News:Health News:NCCN Updates Supportive Care Guidelines for VTE 2Health News:NCCN Updates Supportive Care Guidelines for VTE 3Health News:California Medical Association Joins MedicAlert Foundation to Offer Medical Identification for Members and Patients 2Health News:Healthier Lifestyle Can Cut COPD Symptoms 2Health News:The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014 /PRNewswire/ ... a leading provider of medication and supply management ... a conference call Thursday, July 31, to discuss ... , Omnicell Second Quarter 2014 earnings conference ... 1:30 p.m. PTWho:  , Randall Lipps, chairman, president ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... , HUNTINGTON BEACH, California and ... cancer diagnostics, today announced the,inclusion of its breast cancer ... on the primary therapy of early breast,cancer. The recommendations ... will appear in the August print edition. , ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), ... on the development of prescription drugs that target unmet ... names Moapar(R),and Salvapar(R)), was launched in Germany in May ... was also launched on a preliminary basis in,Belgium. The ...
Cached Medicine Technology:Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: